Co-Diagnostics Inc. has announced the development of a proprietary sample preparation instrument designed to streamline and simplify the workflow for its point-of-care (PoC) Co-Dx PCR Mycobacterium Tuberculosis $(MTB)$ Test. The new device aims to enable decentralized PCR testing across nearly 30,000 primary health centers in India, improving access to life-saving TB diagnostics. Engineered for low-cost and user-friendly operation, the instrument supports both sputum and novel tongue swab samples, with features that allow rapid preparation and enhanced safety for operators. Clinical evaluations of the MTB test using the new device are expected to begin in India before the end of the year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA99495) on October 16, 2025, and is solely responsible for the information contained therein.